01469oam 2200385Ia 450 991069873160332120090421151936.0(CKB)5470000002396542(OCoLC)318922997(EXLCZ)99547000000239654220090421d2008 ua 0enguran|||||||||txtrdacontentcrdamediacrrdacarrierGuidance for industry[electronic resource] safety, efficacy, and pharmacokinetic studies to support marketing of immune globuline intravenous (human) as replacement therapy for primary humoral immunodeficiencyRockville, MD :U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,[2008]i, 15 pages digital, PDF fileTitle from PDF title page (viewed on Apr. 21, 2009)."June 2008."Includes bibliographical references (pages 14-15).Guidance for industry ImmunoglobulinsPharmacokineticsImmunoglobulinsMarketingImmunoglobulinsPharmacokinetics.ImmunoglobulinsMarketing.Center for Biologics Evaluation and Research (U.S.)GPOGPOGPOBOOK9910698731603321Guidance for industry3434577UNINA